Reduction in Corticosteroids Is Associated with Better Health-Related Quality of Life after Liver Transplantation - 23/01/12
, Irene D. Feurer, PhD a, b, Matthew P. Landman, MD, MPH a, Derek E. Moore, MD, MPH a, J. Kelly Wright, MD, FACS a, C. Wright Pinson, MBA, MD, FACS a
Correspondence address: Victor Zaydfudim, MD, MPH, Division of Gastroenterologic and General Surgery, Mayo Clinic, 200 First St SW, Rochester, MN 55905Résumé |
Background |
Corticosteroid use during post-transplant immunosuppression contributes to documented long-term complications in liver transplant recipients. However, the effects of steroids on post-transplant physical and mental health-related quality of life (HRQOL) have not been established. We aimed to test the association between steroid-based immunosuppression and post-transplant HRQOL in liver transplant recipients.
Study Design |
We performed a retrospective analysis of prospective, longitudinal HRQOL measured using the Short Form 36 Health Survey physical and mental component summary scores, Beck Anxiety Inventory, and Center for Epidemiologic Studies Depression Scale. Steroid use (none, low [<10 mg/d], high [≥10 mg/d]) and temporally associated acute rejection (within previous 6 weeks, previous 7 to 12 weeks, and never or >12 weeks before HRQOL measurement) were determined at every post-transplant HRQOL data point. Linear mixed-effects models tested the effects of contemporaneous steroid use and dosing on post-transplant HRQOL.
Results |
The sample included 186 adult liver transplant recipients (mean age 54 ± 8 years, 70% male) with pre- and at least 1 post-transplant HRQOL data point. Individual follow-up post-transplant averaged 21 ± 18 months (range 1 to 74 months). After controlling for pre-transplant HRQOL, time post-transplant, pre-transplant diagnosis group, and temporally associated episodes of rejection, post-transplant high-dose steroid use (≥10 mg/d) was associated with lower physical component summary (p < 0.001) and mental component summary (p = 0.049) scores and increased Beck Anxiety Inventory (p = 0.015) scores. Low-dose steroid use (<10 mg/d) was not associated with post-transplant HRQOL in any model (all p ≥ 0.28).
Conclusions |
High-dose steroid use for post-transplant immunosuppression in liver transplant recipients was associated with reduced physical and mental HRQOL, and increased symptoms of anxiety. There was an association between better HRQOL and steroid reduction to <10 mg/d in liver transplant recipients during a broad follow-up period.
Le texte complet de cet article est disponible en PDF.Abbreviations and Acronyms : BAI, CES-D, HCV, HRQOL, MCS, PCS, SF-36
Plan
| Disclosure Information: Nothing to disclose. |
|
| This study was supported in part by the National Research Service Award T32 HS 013833 (V.Z.) from the Agency for Healthcare Research and Quality, US Department of Health and Human Services, and an educational award from the Novartis Corporation. |
Vol 214 - N° 2
P. 164-173 - février 2012 Retour au numéro
Article précédent
- Creation and Implementation of an Emergency General Surgery Registry Modeled after the National Trauma Data Bank
- Robert D. Becher, J. Wayne Meredith, Michael C. Chang, J. Jason Hoth, H. Randall Beard, Preston R. Miller
- Hepatocellular Carcinoma Within a Noncirrhotic, Nonfibrotic, Seronegative Liver: Surgical Approaches and Outcomes
- Alastair L. Young, Robert Adair, K. Rajendra Prasad, Giles J. Toogood, J. Peter A. Lodge
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?